Stock Evaluator: Insulet Corporation (PODD)

Insulet Corporation PODD

$134.68 -3.24 -2.35%
September 10, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,866,864
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics PODD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $9,340.6 $397.9 77%
Shares Out (Mil) 69.4 40.8 55%
Institutional Ownership 99.7% 83.6% 92%
Float (Mil) 69.1 35.5 54%
Beta 1.09 0.88 65%
Avg Daily Volume (000s) 1,979 323 83%
Price Change
(52-week)
(61.8%) 63.7% 12%
Growth PODD Industry
Median
Percentile
(All Stocks)
Sales (5yr) 24.5% 11.8% 86%
Net Income (5yr) 105.2% (5.8%) 99%
EPS (5yr) 103.4% 10.4% 99
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (18.2%) (15.5%) 38%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 21 23 23
Current EPS $1.587 $6.503 $7.711
Month Ago EPS $1.598 $6.509 $7.726
# Rev Up 1 1 1
# Rev Down 1 0 0
Three Months Ago EPS $1.639 $6.481 $8.090
Year/Year Chg 15.8% 86.9% 166.9%
Financials PODD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $3,053 $119 66%
Net Income (TTM) (Mil) $375 ($9) 75%
EPS (TTM) $5.361 ($0.400) 87%
Operating Cash Flow (TTM) (Mil) $511 ($3) 72%
Net Cash Flow (TTM) (Mil) ($587) $1 5%
Long-Term Debt (Q1) (Mil) $930 $23 65%
Enterprise Value (Q1) (Mil) $10,075 $371 74%
Valuation PODD Industry
Median
Percentile
(All Stocks)
P/B 6.57 2.73 84%
P/E 25.4 25.4 64%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.2 1.4 11%
Ratios PODD Industry
Median
Percentile
(All Stocks)
Gross Margin 71.1% 58.3% 82%
Net Margin 12.3% (6.9%) 68%
ROA 11.3% (12.7%) 89%
ROE 26.0% (12.3%) 85%
Liabilities to Assets 55.1% 46.0% 48%
F-Score 9 4 98%

Insulet Corporation did not pass any screens on 9/10/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors